For research and educational purposes only. Not medical advice.
Pharmacokinetic simulator — Pro tool overview
PK simulator overview for FDA-labeled GLP-1s plus clearly-flagged investigational compounds (retatrutide, cagrilintide), using cited half-life and absorption constants.
Summary
Plot serum-concentration curves over a multi-week dosing schedule using FDA-label and peer-reviewed half-life and absorption constants.
What this tool does
Plots a multi-week serum-concentration curve for the chosen compound given a dosing schedule. Renders a normalized percent-of-peak overlay so different compounds can be compared on the same axis.
How the math works
One-compartment first-order absorption + first-order elimination. Half-life and absorption constants are loaded from `pkConstants.ts`. For approved compounds they trace to the FDA label (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Victoza); investigational compounds (retatrutide, cagrilintide) use cited peer-reviewed pharmacokinetics and are flagged investigational with no FDA label. Steady-state is reached at approximately 4-5 half-lives.
What the tool will not do
It does not personalize for renal function, hepatic function, drug interactions, or pregnancy. It does not infer a dosing schedule from outcomes. The curves are educational and do not constitute prescribing guidance.
Inputs the tool takes
- Compound (semaglutide, tirzepatide, liraglutide, plus investigational retatrutide and cagrilintide)
- Dose per administration
- Frequency (weekly or daily, per the labeled or trial-protocol schedule)
- Number of weeks to simulate
- Optional: a second compound for side-by-side overlay
What the tool returns
- Multi-week serum-concentration curve
- Normalized percent-of-peak overlay
- Steady-state and time-to-steady-state estimates
Cited literature
- Wegovy (semaglutide) FDA label
- Ozempic (semaglutide) FDA label
- Mounjaro (tirzepatide) FDA label
- Zepbound (tirzepatide) FDA label
- Saxenda (liraglutide) FDA label
- Victoza (liraglutide) FDA label
- Urva et al. 2022, Lancet (retatrutide pharmacokinetics)
- Enebo et al. 2021, Lancet (cagrilintide pharmacokinetics)
Constants in pkConstants.ts. FDA labels are the source for approved compounds; investigational compounds (retatrutide, cagrilintide) use cited peer-reviewed pharmacokinetics and are clearly flagged investigational.
See it in action
The pharmacokinetic simulator is a pepSmart Pro tool. See what Pro includes.